USPTO Patent Grants - Therapeutics (A61P)

NF-κB Inhibitors for Cancer, Inflammatory Diseases

The USPTO granted Patent US12606528B2 to the University of Pittsburgh covering compounds that inhibit NF-κB activity and their use in treating cancer, inflammatory conditions, and autoimmune diseases. The patent names Beibei Chen, Toren Finkel, and Yuan Liu as inventors and contains 33 claims. The patent application was filed on November 20, 2020.

Daiichi Sankyo Antibody-Pyrrolobenzodiazepine Derivative Conjugate Cancer Therapy Patent

The USPTO granted patent US12606634B2 to Daiichi Sankyo Company, Limited on April 21, 2026, covering a novel antibody-pyrrolobenzodiazepine derivative conjugate that binds claudin-6 (CLDN6) and claudin-9 (CLDN9) proteins, with applications in cancer therapy. The patent contains 17 claims under CPC classifications A61K 47/6803, A61P 35/00, C07D 487/04, and C07K 16/30.

Condensed Pyrazole Derivatives as Inhibitors of SARM1

The USPTO granted patent US12606558B2 to Disarm Therapeutics, Inc. covering condensed pyrazole derivatives useful as SARM1 inhibitors for treating and preventing axonal degeneration. The patent, granted April 21, 2026, contains 10 claims and names six inventors including Jonathan Bentley Jr. and Robert Owen Hughes.

Regeneron Gets US Patent for Radiolabeled Anti-MET Antibodies

The USPTO granted Regeneron Pharmaceuticals, Inc. Patent US12605473B2 covering radiolabeled anti-MET antibodies and MET×MET bispecific antibodies for immuno-PET imaging. The patent includes 28 claims and covers methods of detecting MET proteins in subjects or samples and methods of monitoring treatment efficacy in MET-expressing tumors. The patent application was filed December 29, 2023.

Johns Hopkins Tolerogenic Antigen-Presenting Cell Patent US12605463B2

The USPTO granted patent US12605463B2 to Johns Hopkins University covering biodegradable particles designed to interact with immune cells and generate immunosuppressive effects. The particles include a polyester or polyester blend with soluble protein or small molecule encapsulated within, and two surface-attached protein types acting as Signal 1 and Signal 2 for immune cell binding and co-stimulation. The invention claims methods for inducing regulatory T cells and treating autoimmune diseases.

Porous Silicon Nanoparticle Drug Delivery System with Reactive Oxygen Species Self-Activation, Kyung Hee University

The USPTO granted Patent US12605462B2 to the University-Industry Cooperation Group of Kyung Hee University for a porous silicon nanoparticle drug delivery system with isothiocyanate moiety conjugated to the surface. The invention generates reactive oxygen species in cells without an external initiator, promoting drug decomposition and release with low side effects due to high biocompatibility.

Regeneron Protein-Drug Conjugates Camptothecin Analogs Patent

The USPTO granted Regeneron Pharmaceuticals, Inc. Patent US12605459B2 covering protein-drug conjugates that combine camptothecin analogs with glutaminyl-modified antibodies for targeted therapeutic delivery. The patent describes methods for producing antibody-drug conjugates using transglutaminase and 1,3-cycloaddition techniques. The granted patent provides Regeneron exclusive rights to the disclosed compositions and methods, with two claims covering the conjugate structures and their therapeutic applications.

SYSTIMMUNE Antibody-Drug Conjugate Patent with Acidic Stabilization Junction

The USPTO granted Patent US12605458B2 to SYSTIMMUNE, Inc. on April 21, 2026, covering an antibody-drug conjugate with a hydrophilic acidic stabilization junction designed to maintain desired pharmacokinetic properties at higher drug loading. The patent, filed June 15, 2018, contains 18 claims and is classified under multiple therapeutic CPC codes including A61P 35/00 (anti-neoplastic), A61P 29/00 (anti-inflammatory), and A61P 37/02 (immunomodulators).

HIP1 Inhibitor Patent US12605456B2, Utah Valley University

The USPTO granted Patent US12605456B2 to Utah Valley University on April 21, 2026, covering inhibitor compounds that target the Huntingtin Interacting Protein 1 (HIP1) enzyme. The patented composition comprises a tripeptide targeting sequence directing the compound to HIP1's active site, conjugated to a C-terminal electrophilic warhead configured to inactivate the enzyme. The patent contains 20 claims.

US12605454B2 - Modified CMV VLPs as Vaccine Platform

USPTO granted Patent US12605454B2 to SAIBA AG for modified Cucumber Mosaic Virus (CMV) virus-like particles (VLPs) incorporating Th cell epitopes for enhanced immune responses as a vaccine platform. The 23-claim patent covers linking antigens to modified CMV VLPs to generate antibody responses. CPC classifications span infectious diseases, autoimmune conditions, metabolic disorders, and neurological applications. The patent application (17714307) was filed April 6, 2022.

University of Minnesota Kinase Degradation Compounds for Cancer Treatment

USPTO granted Patent US12605452B2 to the Regents of the University of Minnesota on April 21, 2026. The patent covers compounds of Formula (I) or (II) comprising Aurora A or CDK4/6 ligands linked to E3 ligase ligands, along with pharmaceutical compositions and methods for treating cancer using such compounds. The patent contains 13 claims.

Actinium-225 Anti-CD45 Antibody Composition Patent Granted

The USPTO granted patent US12605472B2 to Actinium Pharmaceuticals, Inc. on April 21, 2026, covering compositions and methods for treating hematological diseases using actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose. The patent claims 23 compositions and methods of use for treating hemoglobinopathies and hematological malignancies.

Akkermansia muciniphila AK32 Strain for Improving Intestinal Function

The USPTO granted patent US12605414B2 to The Asan Foundation for an Akkermansia muciniphila AK32 strain (Accession No. KCTC 14172BP) and its use for preventing or improving intestinal damage. The patent covers the bacterial strain itself as well as a method for administering an effective amount of the strain or its culture as an active ingredient to treat intestinal damage. Three claims are included in the granted patent.

US12605412B2 - Microbial Compositions for Improving Anticancer Treatment Efficacy

USPTO granted Patent US12605412B2 to Institut Gustave Roussy, covering microbial compositions for enhancing the efficacy of anticancer treatments. The patent claims compositions combining specific bacterial species (Alistipes senegalensis, Dorea longicatena, Eubacterium siraeum) with immune checkpoint inhibitors and/or tyrosine kinase inhibitors, along with diagnostic methods for assessing patient responsiveness to such treatments.

NB Science M3 Mutant Peptide Patent for Myopathy, Obesity, Diabetes

USPTO granted patent US12605431B2 to NB SCIENCE CO., LTD. on April 21, 2026. The patent covers an M3 mutant peptide composition for treating or preventing myopathy, obesity, or diabetes, listing five claims under CPC classifications including A61K 38/4886 and A61P 3/04. The application (18267252) was filed on December 14, 2021.

hUCB Plasma Therapeutic for Neurodegenerative Diseases

The USPTO granted patent US12605409B1 to the University of South Florida covering a method of treating neurodegenerative diseases using plasma derived from human umbilical cord blood (hUCB plasma). The patent discloses that hUCB plasma attenuated hyperactive mitogen responses and reduced caspase 3/7 activity in ALS patient cells, supporting therapeutic efficacy. Assignee: University of South Florida; inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, and Paul R. Sanberg.

Taladegib Pulmonary Fibrosis Treatment Patent Granted to Endeavor BioMedicines

The USPTO granted Patent US12605380B2 to Endeavor BioMedicines, Inc. covering methods of treating pulmonary fibrosis by administering taladegib. The patent, with 29 claims, classifies under CPC codes A61K 31/502 and A61P 11/00. The filing date was September 12, 2025, under Application No. 19327711.

USPTO Grants JBKLAB Cancer Treatment Patent US12605382B2

The USPTO granted US Patent 12605382B2 to JBKLAB Co., Ltd. for a pharmaceutical composition containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as an active ingredient, classified under CPC A61P 35/00 for cancer treatment. The patent, filed on May 3, 2022, contains 12 claims and covers the use of the compound alone and in combination with radiotherapy or other anticancer drugs.

US12605402B2 Oxidizing Acid Solution Patent Grant

The USPTO granted patent US12605402B2 to APR Applied Pharma Research SA covering methods for treating Epidermolysis Bullosa (EB), EGFR inhibitor-induced skin toxicities, Hailey-Hailey Disease (HHD), Buruli Ulcers, and SARS-CoV-2 infections using topical hypotonic acid oxidizing solutions containing hypochlorous acid (HClO). The patent contains 22 claims and was filed on July 2, 2020 under application number 17597220. This grant confers enforceable intellectual property rights to the assignee but does not itself impose compliance obligations on other market participants.

iOnctura PI3K-δ Inhibitor Patent Granted

The USPTO granted Patent US12605389B2 to iOnctura SA covering a PI3K-δ inhibitor compound and its use in methods of treating diseases where PI3Kδ pathway signaling is pathologically implicated. The patent encompasses the compound and its salts for treating cancer and inflammatory or autoimmune diseases, with 14 claims. The patent application was filed on March 29, 2022.

Polymers for Hyperuricemia Treatment Granted to Waterstone

The USPTO granted patent US12605401B2 to Waterstone Pharmaceuticals (Wuhan) Co., Ltd. covering polymers and compositions for binding uric acid and treating hyperuricemia, gout, and related diseases. The patent, with 20 claims, was filed on May 18, 2022 under Application No. 17747006 and lists eight inventors.

Taladegib Patent Grant for Pulmonary Fibrosis Treatment

The USPTO granted patent US12605379B2 to Endeavor BioMedicines, Inc. covering methods of treating pulmonary fibrosis using taladegib. The patent includes 29 claims and covers CPC classifications A61K 31/502 and A61P 11/00. The filing date was September 12, 2025.

PDIA4 Inhibitors Treat Diabetes, Preserve Beta Cells

USPTO has granted Patent US12605353B2 to Academia Sinica, covering disulfide-isomerase A4 (PDIA4) inhibitors for inhibiting pancreatic beta-cell pathogenesis and treating diabetes. The patent discloses drug candidates with IC50 values ranging from 4 micrometers to 300 nanomolars that augment insulin secretion from pancreatic beta-cells. Pharmaceutical companies developing diabetes or metabolic disease therapeutics should monitor this IP landscape for potential licensing, freedom-to-operate, or R&D pathway considerations.

HA-Paclitaxel Conjugate Patent for Treatment of Mesothelioma

USPTO granted Patent US12605355B2 to Fidia Farmaceutici S.p.A. covering HA-paclitaxel conjugate compositions for loco-regional treatment of malignant mesothelioma. The patent, with 13 claims, covers malignant pleural, pericardial, and peritoneal mesothelioma applications, with priority dating to the April 7, 2021 filing.

PanTher Therapeutics Drug Delivery Device Patent (US12605356B2)

The USPTO granted patent US12605356B2 to PanTher Therapeutics, Inc. covering implantable and biodegradable drug delivery devices for direct delivery of active pharmaceutical ingredients to pancreatic tumor tissue. The devices feature a two-layer design where one layer contains the API with a biodegradable polymer and a second layer prevents API release away from the target tissue. The patent names Laura Indolfi and Margaret Lashof-Sullivan as inventors.

mTOR Inhibitor Compound for Neurodegenerative Diseases

The USPTO granted Patent US12605358B2 to ALIAD BIOPHARMA for a novel mTOR signaling pathway inhibitor compound. The invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate symptoms associated with Alzheimer's-type dementia in animal models. The patent covers pharmaceutical compositions for preventing or treating nervous system diseases including neurodegenerative diseases and mTORopathy.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor and Pharmaceutical Use Therefor

The USPTO granted patent US12605359B2 to THE KITASATO INSTITUTE on April 21, 2026, covering a low-molecular weight compound that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) functions. The patent protects the compound represented by formula (I), its pharmaceutically acceptable salts and solvates, and medicaments containing the PCSK9 inhibitor for prevention or treatment of PCSK9-related diseases and disorders. The patent contains 5 claims.

Carboxylated Psilocybin Derivatives and Methods of Using (US12605361B2)

USPTO granted patent US12605361B2 to Enveric Biosciences Canada Inc. covering carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The patent contains 18 claims and is based on Application No. 18227688 filed July 28, 2023. This grant confers exclusive IP rights to the assignee and does not create compliance obligations for third parties.

Oxymetazoline Therapeutic Compositions Stabilized for Long-Term Storage

USPTO granted patent US12605363B2 to RVL Pharmaceuticals, Inc. covering compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long-term storage. The patent includes 20 claims and names Tina deVries and David Jacobs as inventors, with a filing date of December 23, 2022.

Telmisartan Patent for Canine Hypertension Treatment

USPTO granted Patent US12605366B2 to inventors Anne Michelle Traas, Amanda Erickson Coleman, Bianca Natália Ferreira De Moura Lourenco, Kate Elizabeth Creevy, and Scott Alan Brown for telmisartan use in treating hypertension in dogs. The patent covers administration of telmisartan in variable daily dosages over a treatment period. Patent holders gain enforceable exclusivity rights.

Methods of Treatment and/or Prevention of Disorders and Symptoms Related to BKCa and/or SK Channelopathies

USPTO granted patent US12605367B2 on April 21, 2026, covering compounds and compositions for treating neurological and non-neurological channelopathies caused by defects in calcium-activated potassium channels. The patent lists 14 claims targeting conditions including Fragile X Syndrome, autism spectrum disorders, Angelman syndrome, and other neuropathic and neurodegenerative diseases. The filing date was September 15, 2020, with application number 17760612.

Kyoto University Patents Neuroinflammation Suppression Compounds

The USPTO granted Kyoto University Patent US12605368B2 for pharmaceutical compositions that suppress neuroinflammation. The compositions contain compounds that inhibit DYRK1A protein phosphorylation activity. The patent covers uses for nerve cell protection, neuron precursor cell transplantation assistance, and Nrf2 protein stabilization in glial cells.

Celgene Corp Combination Therapy Patent US12605372B2 Granted

The USPTO granted Patent US12605372B2 to Celgene Corporation on April 21, 2026. The patent covers methods of treating cancers by administering Compound A in combination with daratumumab, or Compound A with daratumumab and dexamethasone. The patent contains 19 claims and derives from Application No. 17983762, filed November 9, 2022.

Methods of treating relapsing multiple sclerosis using fenebrutinib 200mg twice daily

USPTO issued Patent US12605376B2 to Genentech, Inc. covering methods of treating Relapsing Multiple Sclerosis using fenebrutinib, a Bruton's tyrosine kinase inhibitor. The patent protects administration of approximately 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof. The patent contains 17 claims and is classified under CPC codes A61K 31/4985, A61P 37/00, and A61P 25/00.

Drug Delivery System and Methods of Using the Same

The USPTO granted Axogen Corporation Patent US12599701B2 for a drug delivery system combining polydioxanone polymer with neuro-regenerative or immunosuppressive agents to form an implantable biomaterial. The patent includes 16 claims covering the method of combining, melting, and extruding the polymer with at least one immunophilin ligand. The invention is classified under CPC codes including A61P 25/02 (nervous system therapeutic activity) and A61L 27/54.

Biodegradable Lung Sealant PEG Hydrogel Patent Granted to Ethicon

USPTO granted patent US12599624B2 to Ethicon, Inc. for a rapid-setting biodegradable lung sealant comprising two multi-arm polyethylene glycol (PEG) compositions. The first PEG composition contains an alkaline buffer and the second contains a mildly acidic buffer, providing optimized setup time and extended working time. The formulation may include tocopherol as a radioprotectant and a colorant for improved visualization against lung tissue. The patent contains 22 claims and is classified under CPC codes A61K and A61P.

Shiseido Granted Patent for Skin Composition Formulations and Methods

USPTO granted Patent US12599623B2 to Shiseido Company, Limited on April 14, 2026. The patent covers body corrective cosmetic formulations and methods of use thereof, including skin treatment compositions. The application was filed on June 29, 2017 under Application No. 15638059 with 13 claims.

Method for Preparing Polydopamine Nanomotor Using Urease and Use of Same

USPTO granted Patent US12599571B2 to POSTECH Research and Business Development Foundation for a biocompatible polydopamine nanomotor using urease. The nanomotor is designed to infiltrate bladder walls in biological environments and remain inside the bladder for extended periods. The patent includes 10 claims covering the preparation method and therapeutic applications.

Probiotic Composition for Improving Soy Protein Proteolysis and Amino Acid Production Activity

USPTO granted patent US12599641B2 to Lactomason Co., Ltd. on April 14, 2026. The patent covers a probiotic composition that improves soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The mixed bacterial strain formulation demonstrates enhanced self-aggregation, hydrophobicity, and intestinal adhesion compared to single-strain alternatives.

House Wellness Foods Probiotic Therapeutic Patent Granted

The USPTO granted Patent US12599638B2 to House Wellness Foods Corporation for a feed and composition comprising Lactobacillus plantarum strain L-137 and a fatty acid. The patent covers compositions for enhancing IL-12 production, immunostimulation, and bacteriostasis. The patent application was filed on September 21, 2021, with 7 claims granted.

Signum Biosciences Chia Seed Extract Patent Granted

The USPTO granted patent US12599642B2 to Signum Biosciences Inc on April 14, 2026. The patent covers compositions derived from Salvia hispanica (chia) seeds and methods of preparation and administration. The 18 claims span dermatological applications including skin care and sunscreen formulations. Third parties face no compliance obligations from this patent grant.

NLRP3 Modulators for Treating Interleukin 1β Diseases

USPTO granted patent US12599616B2 to Zydus Lifesciences Limited for novel substituted sulfonylurea and sulfoximineurea derivatives as NLRP3 modulators for treating interleukin 1β-mediated diseases and conditions. The patent contains 11 claims and 20+ CPC classifications spanning A61K, C07C, C07D, and A61P therapeutic categories.

Tumor Stroma Imaging Agent with FAP Targeting

USPTO granted patent US12599685B2 to Shanghai University of Medicine & Health Sciences for a tumor stroma imaging agent targeting fibroblast activation protein (FAP). The imaging agent exhibits high affinity for FAP, high uptake for malignant tumors with high FAP expression, and high sensitivity and specificity for tumor diagnosis. The patent covers the chemical structure where R is hydrogen or fluorine, and claims the agent's use for malignant tumor diagnosis and treatment with prolonged half-life.

Serum Exosome With High Osteogenesis and High Angiogenesis for Bone Defect Repair

USPTO granted Patent US12599630B2 to Peking University School and Hospital of Stomatology for a serum exosome composition with high osteogenesis and high angiogenesis for bone defect repair. The patent covers exosomes derived from serum during fracture recovery period (weeks 2-5 post-fracture) and methods of preparing and using them for bone defect repair. The patent contains 5 claims.

Megmilk Snow Brand - US12599639B2 Joint Function-Improving Composition Patent

USPTO granted patent US12599639B2 to MEGMILK SNOW BRAND CO., LTD. for a joint function-improving composition containing bacterial cells and/or cultures of Lactobacillus, Lactococcus, Streptococcus, or Bifidobacterium genera combined with a joint function-improving agent. The composition targets prevention or treatment of osteoarthritis and rheumatoid arthritis through chondrocyte growth promotion and suppression of inflammation, cartilage degradation, pain, and neuronal outgrowth factors. The patent covers food, drink, feed, and pharmaceutical applications.

Treatments for Ocular Neovascularization

USPTO granted patent US12599680B1 to 4D Molecular Therapeutics Inc. covering compositions and methods for treating ocular neovascular diseases such as wet age-related macular degeneration. The patent contains 24 claims and expires August 14, 2045.

Tulane Patent for Therapeutic Compound Conjugates US12599674B2

The USPTO granted Patent US12599674B2 to The Administrators of the Tulane Educational Fund covering inventive therapeutic compound conjugates, pharmaceutical compositions, and related methods of treatment and manufacture. The patent, filed June 24, 2025, under application 19247100, contains 23 claims classified under A61K and A61P (oncology).

Halozyme Hypercon Therapeutic Biologics Delivery Patent US12600763B2

USPTO granted patent US12600763B2 to Halozyme Hypercon, Inc. covering compositions and methods for delivering therapeutic biologics for disease treatment. The patent comprises 18 claims for particles containing therapeutic biologics suspended in a liquid carrier, with priority to an August 2022 filing date.

Cancer Vaccine Patent hESCs TLR3 Adjuvant Assigned to INSERM

USPTO granted patent US12599662B2 to INSERM for a cancer vaccine composition using irradiated human embryonic stem cells combined with a TLR3 adjuvant. The patent covers methods for treating cancers including breast cancer by inducing MHC-I presentation of antigens. The patent includes 16 claims.

USPTO Patent US12601742B2 for Endometrial Cancer Treatment Methods

USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research covering methods and materials for assessing and treating endometrial cancer. The patent covers methods for identifying endometrial cancers likely to respond to particular cancer treatments by assessing combinations of mutations and expression levels, such as platinum-based therapies. The patent contains 22 claims.